Introduction {#s1}
============

Inositols are polyols having six-carbon ring structure where each carbon is hydroxylated. A number of these sugar-alcohol isomers are biologically active, of which *myo*-inositol (MI) is the most common ([@B51]). It constitutes a component of membrane phospholipids and mediates osmoregulation ([@B52]). Its phosphorylated derivatives act as second messengers in signal transduction pathways ([@B9]), mediate phosphorylation of proteins ([@B75]), participate in chromatin remodeling and gene expression ([@B64]; [@B80]), and facilitate mRNA export from the nucleus ([@B96]).

Altered MI levels have been observed in the brains of patients of Alzheimer's disease, those suffering from mental disorders, and suicide and stroke victims ([@B55]; [@B50]). High fetal inositol concentrations in the cerebrospinal fluid have been attributed to the pathogenesis of Down's syndrome ([@B1]). Administration of MI has been found to be therapeutic for obsessive-compulsive disorder and panic disorder ([@B78]). Lower frontal cortex MI is linked to the pathophysiology of depression and concomitant sleep symptoms ([@B88]).

MI deficiency causes high accumulation of triacylglycerol, cholesterol, and non-esterified lipids in the mammalian liver. A minimum threshold level of free MI deters the formation of fatty liver ([@B11]; [@B32]; [@B33]). Hence, the metabolic understanding of MI status in any biological organ or system is primarily dependent on MIPS activity and its regulation.

Chemistry {#s1_1}
---------

Chemically inositols are isomers of hexahydroxy-cyclohexanes. Among the nine possible geometrical isomers of inositol, seven are optically inactive or "meso," and the remaining two form a chiral pair. The planar structures of the different isomers of this compound are presented in [**Figure 1**](#f1){ref-type="fig"}. The molecule of MI has one axial and five equatorial hydroxyl groups. The axial hydroxyl group at position 2 is most stable to hydrolysis.

![The planar structure of nine possible stereoisomers of inositol.](fphar-10-01172-g001){#f1}

L-*myo*-inositol-1-phosphate synthase (MIPS) catalyzes the first step in the biosynthesis of all *myo*-inositol-containing compounds ([@B78]). It converts glucose-6-phosphate to *myo*-inositol-1-phosphate (MIP). The phosphate moiety in MIP is subsequently removed by *myo*-inositol-1-phosphatase (IMPase) to produce free MI ([@B52]).

In addition, this compound could also be produced by cyclic synthesis ([@B2]; [@B69]) and the hydrolysis of phosphatidylinositol. Although MIP is the intermediate common to both pathways, two different forms of compound are produced, the L-form by the synthetic pathway and the D-form by the cyclic pathway ([@B68]). However, both the isomers are catalyzed by IMPase ([@B24]), which produces MI.

*Myo*-Inositol in Disease and Medicine {#s1_2}
--------------------------------------

Elevated MI levels have been observed in Alzheimer's disease, gliomatosis cerebri, diabetes mellitus, systemic lupus erythematosus, multiple sclerosis, etc. Further, decreased brain levels of MI were observed in chronic hepatic and hypoxic encephalopathy, stroke, acute thyrotoxic Graves' disease, toxoplasmosis, cryptococcosis, and lymphoma ([@B31]). In the following section, important diseases that are influenced by MI and its derivatives ([**Table 1**](#T1){ref-type="table"}) have been reviewed.

###### 

Pharmacological effects of myo-inositol and its derivatives against different disease symptoms.

  Effective inositol derivative   Affected tissue/organ                                                    Disease/symptom                                                     Reference
  ------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------- ------------------------
  MI                              Intestine (gerbil)                                                       Lypodystrophy                                                       [@B34]
  MI                              Heart (rat)                                                              Left ventricular stiffness                                          [@B71]
  MI                              Liver (rat)                                                              Fatty liver disease                                                 [@B11]; [@B32]; [@B33]
  MI                              Brain (human)                                                            Affective disorder                                                  [@B7]
  MI                              Lung (mouse)                                                             Tumor                                                               [@B93]
  MI                              Brain (human)                                                            Suicidal tendency                                                   [@B82]
  MI                              Liver (mouse)                                                            Cancer                                                              [@B62]
  MI                              Lung (human)                                                             Tumor                                                               [@B38]
  IP~6~                           Heart (rat)                                                              Calcification of vessels                                            [@B27]
  DCI-IPGs                        Ovary (human)                                                            PCOS                                                                [@B74]
  DCI                             Diabetic human                                                           Endothelial dysfunction                                             [@B43]
  DCI                             Diabetic human                                                           Endothelial dysfunction, metabolic syndrome, erectile dysfunction   [@B58]
  PIP~3~                          Nerve tissue, thyroid gland, colon, lung, prostate gland, skin (human)   Cancer                                                              [@B49]; [@B65]; [@B97]
  IP~6~ + MI                      Colon, breast, lung (human)                                              Cancer                                                              [@B91]; [@B92]
  MI                              Brain (human)                                                            Depression                                                          [@B17]; [@B83]
  MI                              Fetal brain (human)                                                      Down's syndrome                                                     [@B78]
  PIP~2~                          Ovary, breast, lung, colon, stomach (human)                              Cancer                                                              [@B25]; [@B97]
  MI                              Brain (human)                                                            Bipolar disorder                                                    [@B77]
  MI                              Brain (human)                                                            Mild cognitive disorder                                             [@B8]; [@B90]
  MI                              Brian (human)                                                            Alzheimer's disease                                                 [@B84]
  DCI/MI ratio                    Diabetic human                                                           Insulin resistance                                                  [@B44]
  MI                              Lung (mouse)                                                             Tumor                                                               [@B39]
  IP~6~ + MI                      Breast (human)                                                           Cancer                                                              [@B4]
  IP~6~                           Prostate gland (human)                                                   Cancer                                                              [@B29]
  DCI                             Ovary (human)                                                            Poor oocyte quality                                                 [@B12]; [@B37]; [@B85]
  PIP~2~                          Brain (human)                                                            Schizophrenia                                                       [@B46]
  MI + DCI                        Ovary (human)                                                            PCOS                                                                [@B57]

DCI, D-chiro-inositol; ED, endothelial dysfunction; IP~6~, Myo-inositol hexakisphosphate/phytic acid; IPG, inositol phosphoglycan; MI, Myo-inositol; PIP~2~, phosphatidylinositol inositol 4,5-bisphosphate; PIP~3~, phosphatidyl inositol 3,4,5-trisphosphate.

Dyslipidemia and Cardiac Diseases {#s1_3}
---------------------------------

Ever since it was known that MI deprivation in diet resulted in fatty liver condition in rats ([@B11], [@B32]; [@B33]), the interest regarding its therapeutic value developed. MI also reduced the accumulation of hepatic triglyceride in the liver ([@B54]). Treatment with MI assisted in the removal of cholesterol from the myocardium, resulting in the decrease in lipid buildup in the heart that improved heart function. The reduction in myocardial lipid content ultimately resulted in the decrease in left ventricular stiffness ([@B71]).

A family of proteins called myotubularins which are actually inositol-3-phosphatases that dephosphorylate PI~3~P and PI(3,5)P~2~ are implicated in cardiomyopathy. It has been found that mutations in the genes coding for the aforementioned proteins caused cardiomyopathy ([@B54]). Nebivolol, a beta-blocker drug, induces vasorelaxation through activation of inositol phosphate metabolism ([@B67]). Calcification of heart vessels is an undesirable attribute of cardiovascular disease (CVD), and IP~6~ acts as a crystallization inhibitor of calcium salts *in vitro*, reducing the calcification of coronary arteries ([@B27]).

Diabetic Complications {#s1_4}
----------------------

It is a known fact that, in diabetic animals, there is limited metabolism of fructose in the nerve system leading to the accumulation of sorbitol and fructose, which is responsible for peripheral neuropathy ([@B26]). This causes a decrease in the motor nerve conduction velocity as well as in the MI concentration of the sciatic nerve at the onset of diabetes ([@B28]). These anomalies could be prevented by the exogenous administration of MI ([@B66]).

Endothelial dysfunction (ED) caused by hyperglycemia and hyperlipidemia is an early feature of diabetes ([@B58]). Inositol phosphoglycans (IPGs) are generated rapidly in response to insulin and have an insulin-like effect *in vivo* and *in vitro* ([@B36]). In human urine, the level of *chiro*-inositol is decreased, while the MI content increased in diabetic subjects. The decreased urinary *chiro*-inositol is inversely correlated to insulin resistance. Administration of D-*chiro*-inositol (DCI) in diabetic humans effectively decreased hyperglycemia and hypertriglyceridemia ([@B43]).

In type 2 diabetic subjects, the higher levels of MI and the lower levels of DCI are referred to as inositol imbalance. *Chiro-*inositol deficiency and imbalance with *myo*-inositol are directly related to insulin resistance ([@B44]).

Cancer {#s1_5}
------

Carcinogenesis in various organs may be inhibited by MI. Significant suppression of liver carcinogenesis by the oral administration of MI has been observed in mice ([@B62]). Benzo\[a\]pyrene (B\[a\]P), a carcinogen derived from tobacco, causes lung tumor in rodents through its metabolite, anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo\[a\]pyrene (B\[a\]PDE). Interestingly, the same metabolite inhibits the differentiation of small airway epithelial cells (SAE) in humans. MI protects SAE cells against such inhibitory effects ([@B38]). When MI was added to dexamethasone (another compound that prevents pulmonary neoplasia), an additive effect was observed on the inhibition of lung carcinogenesis ([@B94]). Administration of MI decreases the multiplicity and size of surface tumors. It also decreases the size of adenocarcinoma, and therefore, it may be utilized for the chemoprevention of early pulmonary lesions ([@B39]).

Striking anticancer effects of IP~6~ and inositol have been demonstrated in experimental models ([@B91]). In colon, breast, and metastatic lung cancer models, the effect of the combination of IP~6~ and MI was significantly better than by either of the two acting alone ([@B91], [@B92]). IP~6~ also inhibits prostate cancer (Pca) cell proliferation and stimulates their apoptotic death. IP~6~ inhibits constitutive and growth factor-induced signaling pathways, which eventually leads to the inhibition of growth and the induction of apoptotic death of Pca cells ([@B29]).

Mental Afflictions and Cognitive Diseases {#s1_6}
-----------------------------------------

Evidences suggest that the MI level in brain is associated with changes in mood state. The MI levels in the frontal coretex of suicide victims and those suffering from bipolar disorder were 23 and 30% lower, respectively, than the normal levels ([@B82]). Patients of major depressive disorder have shown significantly lower MI/creatine ratios. The low levels of MI in the prefronatal/anterior cingulate cortex in major depressive disorder patients may be a consequence of altered glial metabolism ([@B17]). Abnormal level of MI along with glutamate and glutamine was found in the brains of major depressive patients ([@B83]).

Administration of lithium causes a lowering of MI in the critical areas of the brain, and the effect is therapeutic. Lithium reduces MI level in the right frontal lobe in the brains of patients with manic depression. On the other hand, valproic acid (VPA) decreases the intercellular concentrations of inositol by inhibiting the key enzyme of MI biosynthesis, MIPS, in the human brain ([@B76]). Derivatives of VPA, valnoctamide (VCD), and valrocemide (VGD) are potent anticonvulsant drugs ([@B48]; [@B3]). The fact that 1mM VCD and VGD drastically inhibited human brain MIPS activity supports the view that these derivatives act as potential mood stabilizers ([@B77]).

The extra chromosome 21 in Down's syndrome (DS), which leads to dementia later in life, is phenotypically similar to Alzheimer's disease (AD). The presence of approximately 50% higher level of MI in DS patients suggests a gene dose effect of the extra chromosome 21, where the human osmoregulatory sodium/*myo*-inositol cotransporter gene is located. Still, higher levels of MI in older adults with DS are similar to that symptomatic of AD ([@B36]).

Synaptojanin-1 is a polyphosphosphoinositide phosphatase found in the neurons may have a role in the early onset of AD associated with DS. This enzyme is responsible for maximum of the PIP~2~ phosphatase activity in the brain and plays a critical role in synaptic transmission ([@B19]). The AD peptide Aβ42 stimulates PIP~2~ cleavage and leads to abnormal PIP~2~ metabolism in AD ([@B8]). The genes encoding synaptojanin-1 as well as the Aβ42 precursor is located in chromosome 21, the triplication of which is responsible for DS ([@B54]). In DS patients, the level of synaptojanin-1 is increased, and the corresponding level of PIP~2~ is decreased.

People with mild cognitive disorder (MCI) have higher risk of conversion to AD. In MCI, increased manifestation of MI occurs in the parietal white matter (WM), while in AD, the elevation of MI was found throughout the WM ([@B98]). Therefore, MI level in MCI may be regarded as an early indicator of AD ([@B84]).

Abnormalities in signal transduction play a role in the development of mood disorders. Activated PI-PLC cleaves PIP~2~ into IP~3~ and DAG, both of which are crucial molecules for signal transduction ([@B86]). Different PI-PLC enzymes are tissue-specific, and the different expression of some isoforms was described in pathological conditions ([@B47]). A role of PI-PLC β1 in mood disorders has been suggested ([@B46]), and this hypothesis is in sync with the data obtained from schizophrenia models ([@B53]). PI-PLC β1 was also suggested to represent a molecular convergence point of several neurotransmitter pathways implicated in schizophrenia ([@B15]; [@B40]).

Polycystic Ovary Syndrome {#s1_7}
-------------------------

Polycystic ovary syndrome (PCOS) is the most common form of the endocrine metabolic diseases affecting 6--10% of women of reproductive age ([@B20]). Insulin resistance (IR) and compensatory hyperinsulinemia play an integral role in the pathogenesis of this syndrome ([@B61]). IR places these women at an increased risk of the development of cancer, hypertension, dyslipidemia, type 2 diabetes, and CVDs ([@B10]). It is known that some functions of insulin require low molecular weight IPGs ([@B22]) and also that a deficiency in DCI containing IPGs and/or altered DCI metabolism may contribute to IR.

Besides IR, hyperandrogenism is another feature of PCOS. This hyperandrogenism is related to alteration of steroidogenesis in ovary and adrenal glands ([@B73]). Androgens act synergistically with follicle stimulating hormone (FSH) and modify steroidogenesis enzymes ([@B45]) which is also related to IR.

In women with PCOS, administration of DCI improves clinical features of the syndrome ([@B5]). Moreover, combined therapy of MI and DCI improves the metabolic profile of obese PCOS patients, reducing the risk of CVD ([@B57]). MI may be incorporated into membrane phosphatidylinositols, or it may constitute IPGs in response to insulin. After its release, the IPGs interact with tissues involved in insulin action, thus potentiating the effects of insulin ([@B14]). PCOS patients also exhibit an increased DCI/MI ratio (i.e., overproduction of DCI). This in turn leads to MI deficiency in the ovary. A balance between the two inositols is associated with IR and sensitivity ([@B35]).

Epilepsy {#s1_8}
--------

In case of patients with temporal lobe epilepsy (TLE), MI level increases in the areas of seizure focus (temporal lobe) and its concentration decrease in the areas of seizure spread i.e., frontal lobe ([@B95]). In the temporal lobe, the increased MI has been reported as a consequence of induction of Na+/MI cotransporter1 (SMIT1) after seizure activity in the area of seizure focus ([@B63]). The decreased MI in the frontal lobe reflects the osmolyte changes due to secondary effect of seizures. MI is transported from extracellular fluid into the cell through SMIT1. Overexpression of SMIT1 as well as MI supplementation increases intracellular phosphoinositide level and thereby alters phosphoinositide modulated ion channels suggesting the role of SMIT1 in signaling ([@B18]).

In experimental rats, MI treatment significantly reduces the severity of status *epilepticus* induced by kianic acid. The treatment reduced both the frequency and duration of spontaneous recurrent seizures, the main character of epilepsy. In addition, MI had significant effects on SMIT1 and leucine rich repeat-containing 8A, a component of volume regulated anionic channel ([@B87]).

The IMPA2 gene located at human chromosome 18p 11.2 is responsible for febrile seizure (FS). IMPA2 codes for myo-inositol monophosphatase 2 that converts inositol monophosphate to MI and plays important role in phosphatidylinositol signaling pathway ([@B60]).

Discussion {#s2}
==========

It is a foregone conclusion that MI and its derivatives exert various metabolic actions generating therapeutic outcomes. The activities are due to reduction in ROS generation, direct superoxide scavenging, protection of NO signaling, etc. For example, DCI may be considered a therapeutic agent against metabolic syndrome, endothelial dysfunction, and erectile dysfunction in diabetes patients ([@B58]), and MI may act as alternative of metformin, the most popular oral antidiabetic drug, because it interacts directly with insulin target tissues; however, it does not show the side effects of the drug ([@B22]). The insulin like action of MI and DCI is due to the production of inositol glycan secondary messengers. These inositol glycans may modulate cell signaling, and in addition, inositols are incorporated in cell membrane phospholipids ([@B42]).

Depression and schizophrenia are severe psychiatric diseases that affect millions of individuals worldwide, consequently increasing global suicide levels ([@B72]). MI and its derivatives may be a very important adjunct therapy in such cases. The most important role of MI is found in the treatment of bipolar disorder. More often than not, lithium is the first line of defense in such cases. However, lithium treatment often leads to psoriasis and depression. In such cases, MI may act as a preferable alternative since it is effective in mood stabilization as well as in the treatment of psoriasis ([@B41]).

The importance of inositol in cancer lies in the fact that inositol-3-phosphatase is a potent tumor suppressor, and its mutation leads to many types of cancers ([@B49]; [@B65]; [@B97]). On the other hand, activating mutations in PI~3~-kinases have been reported in ovarian, breast, lung, colon, and gastric cancers ([@B25]; [@B97]). In addition, in breast cancer patients, IP~6~ and MI may be a valuable adjunctive therapy. They also help in ameliorating the side effects and improving the quality of life ([@B4]).

In oligoasthenospermia (OA), reduction in the number and motility of spermatozoa takes place. MI plays a crucial role in the osmoregulation of seminal fluid, thereby improving sperm motility. The antioxidant effect of MI also plays important role in the production and regulation of spermatozoa. Therefore, MI could be used in OA patients undergoing an *in vitro* fertilization cycle ([@B30]). ROS affects not only the morphology and motility of spermatozoa but may also damage mitochondrial membrane potential (MMP) which in turn increases ROS production. MI may improve the sperm mitochondrial function, thereby improving sperm parameters in OA patients ([@B16]).

In women with PCOS, the combined therapy of MI plus DCI is able to influence the metabolism leading to improved lipid profile. However, in these patients, enhanced epimerization of MI to DCI takes place in the ovary, leading to excess DCI and less MI ([@B37]). This MI depletion eventually leads to poor oocyte quality ([@B12]). MI supplementation may salvage the situation by improving oocyte quality ([@B85]).

The spurt of research on inositol biochemistry started from the 1960s with different groups taking the lead on various aspects of the work ([@B6]; [@B79]; [@B59], [@B70]; [@B56]; [@B13]; [@B24]; [@B81]; [@B21]). Now, the molecules have again come into focus primarily due to the continued increase in lifestyle diseases and the long quest for effective and non-toxic cure for the same. ROS reduction may be one of the strategies of MI derivatives for its therapeutic functions. In diabetes and heart ailments, ROS generation by NADPH oxidase action and mitochondrial disruption could be inhibited by DCI ([@B89]). IP~3~ signaling may be another mechanism by which MI derivatives influence cellular functions. IP~3~ is responsible for Ca^2+^ release from the ER which raises the cytosolic Ca^2+^, and this in turn activates many enzymes and proteins. Indeed, defective IP~3~ receptors have been found responsible for many neurodegenerative disorders ([@B23]). Thus, MI and its derivatives may well play important roles not only to ameliorate cancers and psychotic diseases but also in many lifestyle diseases like obesity, diabetes, CVD, etc. This report tried to highlight these critical areas.
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